Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Incyte Corp INCY

Healthcare Biotechnology
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is... see more

Recent & Breaking News (NDAQ:INCY)

Incyte to Present at Upcoming Investor Conferences

Business Wire February 20, 2018

Incyte Reports 2017 Fourth-Quarter and Year-End Financial Results, Provides 2018 Financial Guidance and Updates on Key Clinical Programs

Business Wire February 15, 2018

Incyte Corporation to Host Earnings Call

Accesswire February 15, 2018

Earnings Scheduled For February 15, 2018

Benzinga.com  February 15, 2018

Incyte to Present at Upcoming Investor Conference

Business Wire February 6, 2018

Incyte Updates Conference Call Time to Report Fourth Quarter and Year-End Financial Results

Business Wire January 31, 2018

Incyte to Report Fourth Quarter and Year-End Financial Results

Business Wire January 24, 2018

Incyte Corporation Recommends Shareholders Reject Mini-Tender Offer by TRC Capital Corporation

Business Wire January 23, 2018

Incyte and Syros Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms

Business Wire January 8, 2018

35 Biggest Movers From Yesterday

Benzinga.com  January 3, 2018

28 Stocks Moving In Tuesday's Mid-Day Session

Benzinga.com  January 2, 2018

The Market In 5 Minutes: Oil's Strong Open, Cohen's Comeback, And A Look Back At 2017's Best And Worst Stocks

Benzinga.com  January 2, 2018

Incyte to Present at Upcoming Investor Conference

Business Wire December 14, 2017

Four-Year Phase 3 Data Analysis Shows Durability of Response of Jakafi® (ruxolitinib) in Patients with Polycythemia Vera

Business Wire December 10, 2017

Investor Expectations to Drive Momentum within Barracuda Networks, Abraxas Petroleum, Vertex Pharmaceuticals, Incyte, Forum Energy, and S&P Global – Discovering Underlying Factors of Influence

GlobeNewswire November 15, 2017

Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi®) for the Treatment of Essential Thrombocythemia

Business Wire November 15, 2017

ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo

PR Newswire November 5, 2017

Here's What Was Intriguing About Incyte's Q3 Report

Benzinga.com  November 1, 2017

More Than 30 Abstracts Highlighting Data from Incyte’s Portfolio Accepted for Presentation at the 59th Annual ASH Meeting

Business Wire November 1, 2017

Incyte Corporation to Host Earnings Call

Accesswire October 31, 2017